{"acute myeloid leukaemia": 14.71, "adverse event": 2.26, "alopecia": 2.04, "anaemia": 2.73, "aphasia": 3.85, "aplastic anaemia": 43.65, "astrocytoma maligt": 625.91, "bone marrow failure": 29.11, "brain oedema": 8.67, "cholestasis": 3.26, "cytopenia": 5.21, "dermatitis": 3.75, "diabetes insipidus": 74.45, "disease progression": 15.93, "disease recurrence": 10.78, "drug ineffective": 2.53, "drug reaction with eosinophilia and systemic symptoms": 5.1, "drug resistance": 8.62, "drug-induced liver injury": 2.89, "eastern cooperative oncology group performance status worsened": 239.04, "febrile neutropenia": 5.86, "glioblastoma": 347.13, "glioblastoma multiforme": 281.2, "haematotoxicity": 59.99, "hemiparesis": 5.52, "hepatic failure": 2.39, "hepatotoxicity": 4.33, "hydrocephalus": 14.58, "hypermutation": 3826.21, "hypertransaminasaemia": 8.0, "infection": 2.48, "jaundice": 2.28, "leukopenia": 12.08, "liver injury": 3.8, "lymphopenia": 69.64, "maligt neoplasm progression": 7.77, "metastasis": 14.32, "mucosal inflammation": 4.33, "myelodysplastic syndrome": 23.76, "myelosuppression": 9.58, "neoplasm progression": 9.4, "neutropenia": 10.91, "pancytopenia": 24.55, "petechiae": 2.78, "platelet count decreased": 2.75, "platelet transfusion": 103.09, "pneumocystis jirovecii pneumonia": 16.54, "product substitution issue": 2.44, "product use in unapproved indication": 3.41, "recurrent cancer": 32.92, "sepsis": 2.52, "skin reaction": 3.03, "therapeutic product effect incomplete": 3.48, "thrombocytopenia": 31.24, "toxicity to various agents": 3.56, "treatment failure": 4.7, "tumour pseudoprogression": 470.17}